Nachrichten |
| Datum / Uhrzeit |
Titel |
Bewertung |
| 01.08.25 14:27:44 |
Croda International First Half 2025 Ergebnis: EPS: UK£0.44 (vs UK£0.57 in 1H 2024) |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Croda International (LON:CRDA) Erste Hälfte 2025 Ergebnisse
Wichtigste Finanzergebnisse
Umsatz: 855,8 Mio. UK£ (plus 4,9% von 1H 2024). Nettoeinkommen: 61,2 Mio. UK (ab 23% ab 1H 2024). Gewinnspanne: 7,2% (ab 9,8% in 1H 2024). Der Margenrückgang wurde durch höhere Aufwendungen getrieben. EPS: UK£0.44 (ab UK£0.57 in 1H 2024).
AI wird die Gesundheitsversorgung verändern. Diese 20 Bestände arbeiten an allem von der Frühdiagnostik bis zur Drogenentdeckung. Der beste Teil - sie sind alle unter $10bn in marktcap - es gibt noch Zeit, in früh zu bekommen. LSE:CRDA Ergebnis- und Umsatzwachstum 1. August 2025
Alle in der obigen Abbildung dargestellten Zahlen sind für die Dauer von 12 Monaten (TTM)
Croda International verdient Einblicke
In den nächsten 3 Jahren wird der Umsatz durchschnittlich 5,1 % prognostiziert, verglichen mit einer 15%igen Abnahmeprognose für die Chemieindustrie im Vereinigten Königreich.
Leistung der britischen Chemieindustrie.
Die Aktien des Unternehmens liegen vor einer Woche um 9,2%.
Risikoanalyse
Es ist immer noch notwendig, den immer aktuellen Aspekt des Investitionsrisikos zu berücksichtigen. Wir haben 1 Warnzeichen mit Croda International identifiziert und es sollte Teil Ihres Investitionsprozesses sein.
Haben Sie Feedback zu diesem Artikel? Über den Inhalt? Kontaktieren Sie uns direkt. Alternativ, E-Mail Editorial-team (at) einfachwallst.com.
Dieser Artikel von Simply Wall St ist allgemein in der Natur. Wir liefern Kommentare basierend auf historischen Daten und Analystenprognosen nur unter Verwendung einer unvoreingenommenen Methodik und unsere Artikel sind nicht als Finanzberatung gedacht. Es stellt keine Empfehlung dar, Aktien zu kaufen oder zu verkaufen, und berücksichtigt nicht Ihre Ziele oder Ihre finanzielle Situation. Wir wollen Ihnen langfristig fokussierte Analyse durch grundlegende Daten bringen. Beachten Sie, dass unsere Analyse möglicherweise nicht in den neuesten preisempfindlichen Unternehmensankündigungen oder qualitativen Material ausschlaggebend ist. Einfach Wand St hat keine Position in den genannten Beständen.
Kommentare anzeigen |
| 31.07.25 12:22:42 |
Croda International Plc (LON:CRDA) Just Reported Earnings, And Analysts Cut Their Target Price |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
It's been a mediocre week for Croda International Plc (LON:CRDA) shareholders, with the stock dropping 11% to UK£25.49 in the week since its latest interim results. Croda International reported in line with analyst predictions, delivering revenues of UK£856m and statutory earnings per share of UK£1.14, suggesting the business is executing well and in line with its plan. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.LSE:CRDA Earnings and Revenue Growth July 31st 2025
Following last week's earnings report, Croda International's twelve analysts are forecasting 2025 revenues to be UK£1.68b, approximately in line with the last 12 months. Per-share earnings are expected to climb 18% to UK£1.18. In the lead-up to this report, the analysts had been modelling revenues of UK£1.68b and earnings per share (EPS) of UK£1.32 in 2025. So there's definitely been a decline in sentiment after the latest results, noting the real cut to new EPS forecasts.
Check out our latest analysis for Croda International
It might be a surprise to learn that the consensus price target fell 5.8% to UK£36.23, with the analysts clearly linking lower forecast earnings to the performance of the stock price. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Croda International at UK£52.00 per share, while the most bearish prices it at UK£23.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Croda International'shistorical trends, as the 1.6% annualised revenue growth to the end of 2025 is roughly in line with the 1.8% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue shrink 15% annually. So it's clear that not only is revenue growth expected to be maintained, but Croda International is expected to grow meaningfully faster than the wider industry.
Story continues
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Croda International. On the plus side, they made no changes to their revenue estimates - and they expect it to perform better than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Croda International's future valuation.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Croda International going out to 2027, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 1 warning sign for Croda International you should be aware of.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View comments |
| 30.07.25 05:33:56 |
Croda International Plc (LON:CRDA) Shares Could Be 35% Below Their Intrinsic Value Estimate |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Key Insights
Using the 2 Stage Free Cash Flow to Equity, Croda International fair value estimate is UK£40.11 Current share price of UK£25.98 suggests Croda International is potentially 35% undervalued Our fair value estimate is 7.5% higher than Croda International's analyst price target of UK£37.31
Does the July share price for Croda International Plc (LON:CRDA) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. It may sound complicated, but actually it is quite simple!
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
The Calculation
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Levered FCF (£, Millions) UK£172.0m UK£224.0m UK£273.0m UK£295.0m UK£312.0m UK£326.9m UK£340.4m UK£352.8m UK£364.4m UK£375.7m Growth Rate Estimate Source Analyst x4 Analyst x4 Analyst x1 Analyst x1 Est @ 5.75% Est @ 4.79% Est @ 4.11% Est @ 3.64% Est @ 3.31% Est @ 3.08% Present Value (£, Millions) Discounted @ 7.6% UK£160 UK£193 UK£219 UK£220 UK£216 UK£210 UK£203 UK£196 UK£188 UK£180
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = UK£2.0b
Story Continues
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.5%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.6%.
Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = UK£376m× (1 + 2.5%) ÷ (7.6%– 2.5%) = UK£7.5b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= UK£7.5b÷ ( 1 + 7.6%)10= UK£3.6b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is UK£5.6b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of UK£26.0, the company appears quite good value at a 35% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.LSE:CRDA Discounted Cash Flow July 30th 2025
The Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Croda International as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.6%, which is based on a levered beta of 0.995. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
Check out our latest analysis for Croda International
SWOT Analysis for Croda International
Strength
Debt is not viewed as a risk.
Weakness
Earnings declined over the past year.
Dividend is low compared to the top 25% of dividend payers in the Chemicals market.
Opportunity
Annual earnings are forecast to grow faster than the British market.
Trading below our estimate of fair value by more than 20%.
Threat
Dividends are not covered by earnings and cashflows.
Revenue is forecast to grow slower than 20% per year.
Looking Ahead:
Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Croda International, we've put together three pertinent aspects you should assess:
Risks: To that end, you should be aware of the 1 warning sign we've spotted with Croda International . Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for CRDA's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every British stock every day, so if you want to find the intrinsic value of any other stock just search here.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 29.07.25 16:36:18 |
FTSE 100 klettert als Ergebniskaskade |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Die FTSE 100 erzielte am Dienstag einen starken Fortschritt, der durch die Ergebnisse von AstraZeneca und Barclays verstärkt wurde, aber es war ein düsterer Tag für Investoren in Novo Nordisk.
Russ Mould, von AJ Bell, sagte: „Es ist eine geschäftige Woche für Unternehmensverdienste in Großbritannien und den USA, und Investoren haben viele Neuigkeiten zu verdauen. Die neuesten britischen Ergebnisse wurden in der Regel gut aufgenommen. „
Der FTSE 100-Index hat 54,88 Punkte, 0,6%, mit 9,136,32 geschlossen. Der Index hatte früher als 9,163.24 gehandelt.
Die FTSE 250 schließt 158.73 Punkte niedriger, 0,7%, bei 21,793.07 und die AIM All-Share geschlossen 7,27 Punkte, 0.9%, bei 765.75.
In London wiegten die Investoren eine Barrage des Gewinns mit Aktien von AstraZeneca, Barclays, Games Workshop und Entain, die sich höher bewegten, obwohl Croda International kämpfte.
Games Workshop führte den Weg, um 5,4%, wie es sagte, Vorsteuergewinn stieg 29% auf £262,8 Millionen im Geschäftsjahr, das endete 1 von £203 Millionen im Jahr.
The Nottingham, England-basierte Fantasy-Spielfiguren-Hersteller und Einzelhändler sagte Umsatz stieg 17% auf £617,5 Millionen von £525.7 Millionen.
In Bezug auf das starke Ergebnis lag die Gesamtdividende bei 5,20 Pfund, was gegenüber 4,20 Pfund im Vorjahr um 24% gestiegen war.
AstraZeneca, der größte FTSE 100 Bestandteil, stieg 3,4%.
Das in Cambridge ansässige Pharmaunternehmen sagte, dass der Vorsteuergewinn 30 % auf 3,13 Milliarden Dollar im zweiten Quartal 2025 von 2,4 Milliarden Dollar pro Jahr vor, oder um 34% bei konstanter Währung.
Der Umsatz stieg um 12% auf 14,46 Milliarden Dollar im Quartal von 12,94 Milliarden Dollar im Jahr vor, oder um 11% in konstanter Währung, vor dem Konsens von Visible Alpha von 14,31 Milliarden Dollar.
Der Umsatz wurde durch ein zweistelliges Wachstum in der Onkologie und BioPharmaceuticals getrieben, wobei in allen großen geografischen Regionen zugenommen hat.
Entain stieg um 0,8%, als es die Führung an seiner BetMGM Joint Venture, während Barclays 2,5% nach gut aufgenommenen Ergebnissen und trotz fehlender Orientierungswanderung.
Bank of America sagte, Barclays druckte eine „gute“ Ergebnisreihe mit dem zugrunde liegenden Gewinn um 11% über dem Konsens, vor allem durch höhere Einkommen (insbesondere nicht-interessierte Einkommen) und geringere Beeinträchtigungen.
Aber Croda International war um 10%. Der Spezialchemikalienhersteller erzielte in der ersten Hälfte einen verbesserten Umsatz, obwohl die Beeinträchtigungen seine untere Linie begrenzten.
Der Vorsteuergewinn von Croda im ersten Halbjahr 2025 verringerte sich um 19% auf £ 85,5 Mio. von £106,1 Mio. trotz der Umsatzsteigerung von 4,9% auf £ 855,8 Mio. von £815,9 Mio. Der bereinigte Vorsteuergewinn stieg jedoch um 8,4% auf £138 Millionen ab £127,3 Millionen.
Geschichte geht weiter
Der Umsatz sank leicht unter dem unternehmensbedingten Konsens von 857 Millionen Pfund. Sie schlagte jedoch auf den Gewinn, da der bereinigte Gewinnkonsensus vor Steuern auf £136,6 Mio. lag.
Die Stimmung breitete sich nach Europa aus. Der CAC 40 in Paris stieg um 0,7%, während der DAX 40 in Frankfurt um 1% stieg.
Allerdings stürzte der Novo Nordisk in Dänemark um 23 %, da er die Umsatz- und Gewinnberatung im Gesamtjahr senkte, indem er schwächere als erwartete Aufnahme von Schlüsselgewichtsverlusten und Diabetesbehandlungen in den USA anführte.
Novo Nordisk senkte seine Umsatzwachstumsleitlinien von 2025 auf 8% bis 14%, von 13% auf 21%. Es erwartet nun ein operatives Ergebniswachstum von 10% bis 16%, das von einem vorherigen Bereich von 16% auf 24% reduziert wird.
Das Unternehmen gab eine langsamere als erwartete Wegovy Aufnahme in den US-amerikanischen Fettleibigkeitsmarkt, verbunden durch den anhaltenden Verkauf von Compounded GLP-1s, eine wettbewerbsfähigere Landschaft für Ozempic in den USA, und weniger erwartete Wegovy Penetration in ausgewählten internationalen Märkten.
Die Analysten von Jefferies sagten, dass der 2025-Aussichtsschnitt einen hohen einstelligen Prozentanteil an zugrunde liegenden Gewinnprognosen absinkt.
In New York am Dienstag lag der Dow Jones Industrial Average um 0,3%, der S&P 500 um 0,1% niedriger als der Nasdaq Composite.
Ein Bericht des Konferenzrats zeigte eine leichte Abholung des Verbrauchervertrauens, wenn auch von niedrigen Niveaus, während eine weitere Veröffentlichung einen größeren Rückgang der Arbeitsöffnungen zeigte.
Am Mittwoch wird von der Federal Reserve erwartet, dass die Zinsen unverändert bleiben.
Laut dem CME FedWatch Tool ist es in der Nähe zu beachten, dass die Fed in dieser Woche die Rate auf der 4.25%-4.5% Bereich halten wird. Die Fed fand in jedem der ersten vier Treffen dieses Jahres statt. Seine letzte Kürzung war im Dezember, ein 25 Basispunkte Trimmen auf die Bundesgeld-Range.
Ein fünfter aufeinanderfolgender Halt befindet sich während des letzten Treffens vor einer Sommerpause. Ein „Warte und siehe“-Ansatz wird wahrscheinlich die Botschaft des Vorsitzenden Jerome Powell bei der anschließenden Pressekonferenz sein, Analysten bei Morgan Stanley vorhersagen.
„Wir denken, dass der Vorsitzende Powell ausgeglichen bleiben wird und beide Risiken für die Inflation und die Prognosen für die Zinssenkungen in diesem Jahr erkennen wird“, sagte Morgan Stanley.
Die Aufmerksamkeit wird sich auf jede Unzufriedenheit in den Reihen des Bundes offener Marktkomitees konzentrieren, wo Gouverneure Michelle Bowman und Christopher Waller einen Zinsabbau zurückzahlen können.
Inzwischen trafen sich chinesische und US-Delegationen für ihren zweiten Tag der Handelsverhandlungen in Stockholm, wobei beide Seiten darauf abzielten, einen Waffenstillstand zu verlängern, der in zwei Wochen endet.
Weder die Seite hat bisher Informationen über das, was in den Gesprächen, die am Montag begann, veröffentlicht.
Joshua Mahony in Rostro sagte: „Es gibt eine Erwartung, dass eine Verlängerung der Tariffrist mit China einen Weg für Xi Jinping und Donald Trump eröffnen wird, um persönlich zu treffen und Hoffnungen auf ein bevorstehendes Handelsabkommen zwischen den zwei größten Volkswirtschaften der Welt zu erhöhen. „
Das Pfund verringerte sich auf 1.3337 Dollar am Dienstag Nachmittag in London, im Vergleich zu 1.3403 Dollar an den Aktien nahe am Montag. Der Euro gehandelt mit 1,1537 Dollar, niedriger gegen 1,1620 Dollar. Gegen den Yen war der Dollar bei 148,38 Yen etwas niedriger als 148,45 Yen.
Die Rendite der US 10-Jahre Die Schatzkammer lag bei 4,35 %, beschnitten von 4,42 %. Die Rendite der USA 30 Jahre Die Schatzkammer war von 4,96% auf 4,88% begrenzt.
Auf der Wall Street war Merck ein weiterer Drogenhersteller in den Nachrichten mit Aktien um 4,8%, da es Pläne angekündigt, 3 Milliarden Dollar jährlich bis Ende 2027 zu sparen, und verschärfte Volljahresberatung, da der Umsatz des zweiten Quartals unter den Erwartungen fiel.
Die Rahway, New Jersey-basierte Pharmafirma sagte, GAAP Nettoeinkommen fiel 19% auf 4,43 Milliarden Dollar im zweiten Quartal 2025 von 5,46 Milliarden Dollar pro Jahr vor.
Der Umsatz sank von 16,11 Milliarden Dollar im Jahr vor 1,9% auf 15,81 Milliarden Dollar, fehlte LSEG Konsens von 15,89 Milliarden Dollar.
Der Verkauf von Human-Papillomavirus-Droge, Gardasil, hat 55% auf 1,13 Milliarden Dollar wegen der geringeren Nachfrage in China geklumpt.
Brent Öl wurde am Dienstag um 70,74 Dollar pro Barrel in London zitiert, von 69,65 Dollar spät am Montag. Gold stieg auf 3,327,45 Dollar eine Unze gegen 3,314,26 Dollar.
Die größten Steiger auf der FTSE 100 waren Games Workshop, bis 830p bei 16,090p; AstraZeneca, bis 368p bei 11,158p; Endeavour Mining, bis 66p bei 2,332p; Barclays, bis 10p bei 371.2p; und Rolls-Royce, bis 24.6p bei 1.006p.
Die größten Faller auf der FTSE 100 waren Croda International, unter 301p bei 2,598p; Rentokil Initial, unter 12,9p bei 348,1p; Glencore, unter 10,8p bei 305,9p; Unite Group, ab 21,5p bei 764.5p; und Whitbread, ab 86p bei 3,108p.
Mittwochs lokaler Firmenkalender hat Halbjahresergebnisse von Verteidigungshersteller BAE Systems, Asien-fokussierten Kreditgeber HSBC, Pharmafirma GSK, Bergleute Rio Tinto und Glencore und Hausbauer Taylor Wimpey.
Der globale Wirtschaftskalender am Mittwoch sieht Zinsentscheidungen in den USA und Kanada und US-Wachstumszahlen.
Beitrag von Alliance News.
Kommentare anzeigen |
| 21.07.25 09:28:00 |
Beauty and Personal Care Surfactants Marktchancen und Strategien Report 2025-2034 | China tritt als Key Player mit $628 |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
**Schöne und persönliche Pflege Surfactants Markt Überblick**
Der globale Schönheits- und Pflege-Tenside-Markt wird bis 2034 auf 19,78 Milliarden US-Dollar projiziert, die von E-Commerce-Wachstum, Haarpflegenachfrage und nachhaltiger Innovation angetrieben werden.
**Market Größe und Wachstum**
* Der globale Schönheits- und Personalpflege-Tenside-Markt erreichte 2024 einen Wert von fast 11,15 Milliarden Dollar und wird voraussichtlich bis 2029 auf 15,01 Milliarden US-Dollar mit einer jährlichen Wachstumsrate von 6,14% wachsen.
* Der Markt wird voraussichtlich von 2029 bis 2034 bei einem CAGR von 5,67% wachsen.
**Regionale Aufschlüsselung**
* Asia-Pacific war die größte Region auf dem Markt für Schönheits- und Körperpflege-Tenside, die im Jahr 2024 36,31% oder 4,04 Milliarden US-Dollar betrug.
* Nordamerika, Westeuropa und der Mittlere Osten werden bei CAGRs von 6,78%, 6,51% und 6,51% wachsen.
**Market Segmentierung*
* Der Markt ist unterteilt in:
+ Nicht-ionische Tenside, die im Jahr 2024 43,09% oder 4,8 Milliarden US-Dollar betragen.
+ kationische Tenside, die im Jahr 2024 22,35 % oder 2,7 Mrd. $ ausmachen.
+ Amphotere Tenside, die im Jahr 2024 11,65 % oder $1,35 Milliarden betragen.
+ anionische Tenside, die im Jahr 2024 15,29% oder 1,75 Milliarden Dollar betragen.
**Wettbewerbslandschaft*
* Die zehn Top-Konkurrenten auf dem Markt machten 2023 auf 7,59% des Gesamtmarktes aus.
* Schlüsselakteure wie Croda und BASF führen diese fragmentierte Industrie.
**Trends und Möglichkeiten*
* Der Markt wird von E-Commerce-Wachstum, Haarpflegenachfrage und nachhaltiger Innovation angetrieben.
* Zu den wichtigsten Trends zählen die zunehmende Nachfrage nach personalisierter Schönheit, die wachsende Bedeutung für nachhaltige persönliche Pflegestoffe, die Veränderung von Konsum-Lifestyles und günstige Regierungsinitiativen.
**Herausforderungen und Einschränkungen*
* Der Markt wird durch Störungen der Lieferkette und Schwankungen der Rohstoffpreise behindert.
* Zu den wichtigsten Herausforderungen gehören regulatorische Verbote, Hautempfindlichkeitsbedenken und Störungen der Lieferkette.
**Future Outlook**
* Der Markt wird voraussichtlich von 2029 bis 2034 bei einem CAGR von 5,67% wachsen.
* Zu den wichtigsten Trends zählen die steigende Nachfrage nach wasserlosen Produkten, die steigende Nachfrage aus der Haarpflegeindustrie und das wachsende Bewusstsein für die Haut- und Haarpflege. |
| 17.07.25 13:55:01 |
Croda International (COIHY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Shares of Croda International PLC Unsponsored ADR (COIHY) have been struggling lately and have lost 6.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.
While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.1-month candlestick chart for COIHY
Understanding Hammer Chart and the Technique to Trade It
This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Increases the Odds of a Turnaround for COIHY
There has been an upward trend in earnings estimate revisions for COIHY lately, which can certainly be considered a bullish indicator on the fundamental side. That's because a positive trend in earnings estimate revisions usually translates into price appreciation in the near term.
The consensus EPS estimate for the current year has increased 1.6% over the last 30 days. This means that the Wall Street analysts covering COIHY are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
Story Continues
If this is not enough, you should note that COIHY currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Moreover, a Zacks Rank of 2 for Croda International is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Croda International PLC Unsponsored ADR (COIHY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments |
| 15.04.25 05:40:30 |
Croda International (LON:CRDA) shareholders have endured a 62% loss from investing in the stock three years ago |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Croda International Plc (LON:CRDA) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline in the share price in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 44% lower in that time. Shareholders have had an even rougher run lately, with the share price down 14% in the last 90 days.
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
We've discovered 1 warning sign about Croda International. View them for free.
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
Croda International saw its EPS decline at a compound rate of 21% per year, over the last three years. This reduction in EPS is slower than the 29% annual reduction in the share price. So it seems the market was too confident about the business, in the past.
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).LSE:CRDA Earnings Per Share Growth April 15th 2025
We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. Dive deeper into the earnings by checking this interactive graph of Croda International's earnings, revenue and cash flow.
What About Dividends?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Croda International the TSR over the last 3 years was -62%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.
A Different Perspective
Investors in Croda International had a tough year, with a total loss of 41% (including dividends), against a market gain of about 3.6%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Croda International , and understanding them should be part of your investment process.
Story Continues
Croda International is not the only stock that insiders are buying. For those who like to find lesser know companies this freelist of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 31.03.25 14:12:07 |
Returns On Capital Signal Tricky Times Ahead For Croda International (LON:CRDA) |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. However, after briefly looking over the numbers, we don't think Croda International (LON:CRDA) has the makings of a multi-bagger going forward, but let's have a look at why that may be.
Understanding Return On Capital Employed (ROCE)
For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Croda International, this is the formula:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.073 = UK£232m ÷ (UK£3.5b - UK£337m) (Based on the trailing twelve months to December 2024).
So, Croda International has an ROCE of 7.3%. Ultimately, that's a low return and it under-performs the Chemicals industry average of 9.8%.
Check out our latest analysis for Croda International LSE:CRDA Return on Capital Employed March 31st 2025
In the above chart we have measured Croda International's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Croda International .
What The Trend Of ROCE Can Tell Us
In terms of Croda International's historical ROCE movements, the trend isn't fantastic. Over the last five years, returns on capital have decreased to 7.3% from 21% five years ago. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It may take some time before the company starts to see any change in earnings from these investments.
The Key Takeaway
In summary, Croda International is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. Since the stock has declined 24% over the last five years, investors may not be too optimistic on this trend improving either. On the whole, we aren't too inspired by the underlying trends and we think there may be better chances of finding a multi-bagger elsewhere.
One more thing to note, we've identified 1 warning sign with Croda International and understanding it should be part of your investment process.
Story Continues
While Croda International may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this freelist here.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 28.03.25 08:57:14 |
FTSE 100 LIVE: London opens cautiously as Trump car tariffs throw spanner in the works of growth |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
The FTSE 100 (^FTSE) moved cautiously at the open on Friday, as British carmakers prepared to meet with the government to discuss how to respond to US president Donald Trump placing 25% tariffs on car imports from next week, according to a BBC report.
US levies are due to come into effect on Thursday next week. Cars are the UK's biggest export to the US. Last year 101,000 were exported, worth £9bn.
UK officials are trying to negotiate lower levies before the deadline.
The tariffs could throw a spanner in the works of UK growth plans, with warnings from the the Office of Budget Responsibility (OBR) that becoming embroiled in a trade war could undo the £9.9bn headroom chancellor Rachel Reeves has built into the economy.
London's premier index was almost flat after the opening bell, hovering just above the flatline. Top risers in the index included SSE (SSE.L), Endeavour Mining (EDV.L) and National Grid (NG.L). Engine-maker Rolls-Royce (RR.L) dropped 1.9% in early trade. Germany's DAX (^GDAXI) fell 0.5%, while the CAC 40 (^FCHI) in Paris dipped 0.4%. The pan-European STOXX 600 (^STOXX) traded 0.1% lower.LIVE7 updates
3 mins ago
Lucy Harley-McKeown
US inflation in focus
Neil Wilson, analyst at TipRanks, said: 33 mins ago
Lucy Harley-McKeown
Retail sales: Sentiment 'remains fragile'
Jacqueline Windsor, head of retail at PwC UK, said: 1 hr ago
Lucy Harley-McKeown
UK economy sees modest growth in fourth quarter
Pedro Goncalves writes:
The UK economy posted modest growth in the final quarter of 2024, with gross domestic product (GDP) increasing by 0.1% between October and December, which was unchanged from previous estimates, according to the latest figures from the Office for National Statistics (ONS).
This follows a period of stagnation, with zero growth recorded in the third quarter. However, the ONS also reported a slight dip of 0.1% in GDP for January 2025.
Richard Carter, head of fixed interest research at Quilter Cheviot, said: "The UK economy continues to tread water, with today’s national accounts confirming just how anaemic growth was at the end of 2024. Real GDP rose by just 0.1% in the final quarter, driven largely by modest growth of 0.1% in the services sector and 0.3% in construction.
"The broader picture remains one of stagnation, with GDP per head estimated to have fallen by an unrevised 0.1% and underlying weakness across key areas such as business investment and production." Today at 8:02 AM UTC
Lucy Harley-McKeown
Hardware and clothes shops boost February retail sales
UK retail sales ticked up in February, with growth spurred by strong performances at department stores, hardware shops and fashion. Meanwhile, food sales were more subdued.
“After a very strong January, food sales fell back this month, particularly across supermarkets," said ONS senior statistician Hannah Finselbach.
“It was a positive month for household goods stores with their largest rise since April 2021, driven by hardware store sales. Clothing sales also picked up a little, due to falling prices from widespread discounting.
“Looking at the wider trend, retail sales are now showing growth across both the three-month and annual period, but remain below pre-pandemic levels.” Today at 7:57 AM UTC
Lucy Harley-McKeown
Here's that US futures chart Today at 7:56 AM UTC
Lucy Harley-McKeown
US stock futures slip
From our US team:
US stock futures edged lower as Wall Street continues to grapple with President Trump's escalating trade war.
Futures attached to the Dow Jones Industrial Average (YM=F) slipped 0.10%, the benchmark S&P 500 (ES=F) fell 0.1% and the tech-heavy Nasdaq Composite (NQ=F) dipped 0.2%.
Stocks have had a rollercoaster of a week, starting off on a high on hopes that Trump would temper his tariff plans and then abruptly diving on Wednesday upon news of new duties on auto imports.
Markets continued to slide Thursday as Wall Street digested Trump's 25% levies on foreign cars along with more hawkish comments on what lies ahead in the trade war. April 2, the date when broad reciprocal tariffs are set to take effect, is looming large. Today at 7:54 AM UTC
Lucy Harley-McKeown
Good morning!
Hello from London. It's been a busy week — what with UK chancellor Rachel Reeves' spring statement and yet more tariff wrangling from president Donald Trump. This morning we've also had a GDP print for the last quarter of 2024.
Coming up:
— GfK's consumer confidence survey
— More detail on UK government borrowing
Let's get to it.
View Comments |
| 15.03.25 08:21:55 |
Croda International Full Year 2024 Earnings: EPS Misses Expectations |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Croda International (LON:CRDA) Full Year 2024 Results
Key Financial Results
Revenue: UK£1.63b (down 3.9% from FY 2023). Net income: UK£158.5m (down 7.3% from FY 2023). Profit margin: 9.7% (in line with FY 2023). EPS: UK£1.14 (down from UK£1.23 in FY 2023).LSE:CRDA Revenue and Expenses Breakdown March 15th 2025
All figures shown in the chart above are for the trailing 12 month (TTM) period
Croda International EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%.
The primary driver behind last 12 months revenue was the Consumer Care segment contributing a total revenue of UK£920.0m (57% of total revenue). Notably, cost of sales worth UK£894.2m amounted to 55% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to UK£422.8m (73% of total expenses). Explore how CRDA's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.9% decline forecast for the Chemicals industry in the United Kingdom.
Performance of the British Chemicals industry.
The company's shares are down 4.5% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Croda International that you should be aware of.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
